Neurogene Inc (NGNE)
40.67
+4.25
(+11.67%)
USD |
NASDAQ |
Jul 01, 16:00
40.59
-0.08
(-0.20%)
After-Hours: 20:00
Neurogene Total Assets (Quarterly): 195.35M for March 31, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 195.35M |
| September 30, 2023 | 74.01M |
| Date | Value |
|---|---|
| June 30, 2023 | 85.79M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
74.01M
Minimum
Sep 2023
195.35M
Maximum
Mar 2024
118.38M
Average
85.79M
Median
Jun 2023
Total Assets (Quarterly) Benchmarks
| Taysha Gene Therapies Inc | 153.00M |
| CEL-SCI Corp | 30.05M |
| AIM ImmunoTech Inc | 16.19M |
| IGC Pharma Inc | 9.902M |
| NovaBay Pharmaceuticals Inc | 5.357M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 24.57M |
| Shareholders Equity (Quarterly) | 170.78M |